Market Overview
The Global Cell Therapy Market is expected to reach a value of
USD 5.9 billion in 2023, and it is further anticipated to reach a value of
USD 26.2 billion by 2032 at a
CAGR of 17.9%.
The Global Cell Therapy Market is primarily focused on the research, development and production of cell-based therapies that are used in the treatment of cancer, cardiovascular disease, musculoskeletal disorders, autoimmune disorders and rare health conditions. Cell therapy is a type of regenerative medicine that uses live human blood cells (stem cells, lymphocytes, dendritic cells & others) for the treatment of chronic, acute & rare medical conditions. This market offers a wide range of cellular products such as stem cell therapies, CAR-T cell therapies, tissue-engineered products and others, which are specifically designed according to specific medical conditions. The ongoing research regarding the development of cell therapy leads to the discovery of formulations and methods that significantly impact the growth of this market. These ongoing research and technological advancements in cell therapy procedures are prominently expanding the capabilities and application of this medical and healthcare sector.
Market Dynamic
The market dynamics of the Global cell therapy market can be influenced by various factors that impact the development, commercialization and adoption of cell-based therapies in the healthcare sector. The ongoing research and technological advancements in cell therapy, as well as the development of new therapies, drive the growth of this market. The growth of research institutions, hospitals and the healthcare sector subsequently impacts the growth of the global cell therapy market, as they are shifting the focus of research on producing safer, more effective, and innovative medical treatment that will push the boundaries of present treatment plans for many rare diseases.
Regulatory bodies like the CDC, WHO, and FDA in the United States and their counterparts all over the world play a crucial role in shaping this market. They approve and assess the medicines and therapies before they are released on the market. The results of the clinical trials and research studies significantly affect the cell therapy market. The positive outcomes of these trials can revolutionize this market, whereas negative results can hinder years’ worth of research and growth. These approvals and regulations in the cell therapy market impact the growth of the global cell therapy market.
Research Scope and Analysis
By Therapy Type
In terms of the type of therapy that is used in the treatment of patients, Autologous therapy dominates this market as it holds 93.1% of the market share in 2023 and is expected to show projected growth in the forthcoming year of 2032. Autologous therapy dominates this market because it involves the use of patient's own blood cells for their treatment. This personalized and specially designed treatment therapy to treat specific medical conditions according to patients' requirements is generally safer due to the compatibility of the cells to the patient's immune system, as it reduces the likelihood of adverse reactions and minimizes the risk of graft versus host disease or rejection which is commonly associated with allogeneic therapies.
Additionally, these therapies can be customized according to the specific needs of each patient, making them ideal for medical conditions that require personalized treatment like cancer and autoimmune diseases. Autologous cell therapy holds a major portion of this market because it can be applied to a broad range of medical conditions from dermatology to the treatment of autoimmune disorders. In other words, autologous cell therapy dominates the global cell therapy market because it is preferred by healthcare professionals for its higher success rate, compatibility with patients and broad clinical applicability.
By Therapeutic Area
Based on therapeutic area, Oncology, a branch of medicine dedicated to the study and treatment of cancer, dominates this segment as it holds 39.2% of the market share in 2023 and is projected to show significant growth in this market in the forthcoming years as well.
Cancer is a leading cause of morbidity and high mortality rates globally. That's why the need for an effective and innovative treatment for this disease is essential. The high number of cancer cases around the world drives the substantial demand for its innovative and effective treatment. Cell therapy holds great potential in targeting and treating various types of cancer cases. In the case of cancer, cell therapy offers innovative and personalized treatment plans according to patients' medical condition. Cellular therapies like CAR-T cell therapy have shown a remarkable success rate in treating hematologic malignancies like leukaemia and lymphoma.
Oncology remains the primary focus for research and development in the medical field and it is also encouraged by both government and private organizations as they provide funding and resources for further studies. Despite significant progress in oncology, there are still cases when patients with aggressive forms of cancer cannot be saved. In such cases, cell therapy offers new hope to patients who may not respond to conventional therapies. So, the potential to offer effective, targeted and potentially curative treatment for various cancer types has positioned oncology at the forefront of the cell therapy market.
The Cell Therapy Market Report is segmented on the basis of the following:
By Therapy type
• Autologous Therapies
o Stem Cell Therapies
BM, Blood & Umbilical Cord-derived Stem Cells
Adipose-derived cells
Others
o Non-Stem Cell Therapies
T-cell Therapies
Others
• Allogenic Therapies
o Stem Cell Therapies
Hematopoietic Stem Cell Therapies
Mesenchymal Stem Cell Therapies
o Non-Stem Cell Therapies
Keratinocytes & Fibroblast-based Therapies
Others
By Therapeutic Area
• Oncology
• Cardiovascular Disease (CVD)
• Musculoskeletal Disorders
• Dermatology
• Others
Regional Analysis
North America, asserts its dominance in the global cell therapy market, as it holds 67.1% of the market share in 2023 and is expected to show significant growth in the upcoming period of 2032. The reason behind this region's dominance can be credited to its well-developed ecosystem that harbours a highly advanced healthcare infrastructure, which facilitates the development and research on cell therapies.
Additionally, this region is also home to many world-renowned research institutions and universities like Johan Hopkins University, Harvard University and others which are pioneers in the research of cell therapies, contributing to the development of the medical field.
Regulatory bodies like the U.S. Food and Drug Administration (FDA) have established clear pathways for the growth and approval of cell therapy treatment plans. This regulatory support by the government provides a level of assurance to the companies and investors to invest in this region. These factors collectively position this region as a key player in the development of the global cell therapy market. North America's advanced healthcare infrastructure, strong research capabilities, regulatory support and early adoption and development of cell therapy have positioned it as a dominant region in the global cell therapy market.
By Region
North America
• The U.S.
• Canada
Europe
• Germany
• The U.K.
• France
• Italy
• Russia
• Spain
• Benelux
• Nordic
• Rest of Europe
Asia-Pacific
• China
• Japan
• South Korea
• India
• ANZ
• ASEAN
• Rest of Asia-Pacific
Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America
Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Israel
• Egypt
• Rest of MEA
Competitive Landscape
The competitive landscape of the cell therapy market is marked by intense competition among the major players vying for market share and seeking to get a competitive edge over others. This market sees the collaboration of pharmaceutical companies, biotechnology firms, academic research institutes and emerging startups. Major key players in this market like Novartis, Gilead Sciences, Johanson & Johnson are at the forefront of the global cell therapy market as they are heavily investing in research and development of a new product catalogue. Additionally, academic institutions like Harvard University, the University of California and Berkeley have contributed to the growth of the cell therapy market through groundbreaking research many times.
There are many instances when the research is translated into clinical operations and is commercialized. Large pharmaceutical companies frequently partner with smaller biotech firms to develop and gain access to cutting-edge cell therapy technologies. The key players in this market are Novartis AG, Gilead Sciences Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., JCR Pharmaceutical Company Limited, Bluebird Bio Inc., Dendreon Corporation and others.
Some of the prominent players in the Global Cell Therapy Market are:
• Novartis AG
• Gilead Sciences Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services Inc.
• JCR Pharmaceutical Company Limited
• Tego Science
• Atara Biotherapeutics
• Takeda Pharmaceutical Company Limited
• Bluebird Bio Inc.
• Dendreon Corporation
• Other Key Players
COVID-19 Pandemic & Recession: Impact on the Global Cell Therapy Market:
The Global Cell Therapy Market faced substantial challenges during the COVID-19 pandemic and the resulting economic recession. The pandemic disrupted the ongoing clinical trials as the timeline of the project was temporarily delayed due to safety concerns. Also during the initial phase of the pandemic, most of the resources were redirected to provide aid to the COVID-19 patients. This phase affected the timeline of research design and release of the therapies in the medical market. During the initial phase of COVID-19, the global supply chains were disrupted affecting the availability of necessary materials and components for cell therapy manufacturing.
This posed a major challenge for the global cell therapy market. While initially, the pandemic disrupted the funding and investments in the research projects about cell theory it also highlighted the importance of medical research and biotechnology. As a result, there has been a rise in funds and investments in the life science and biotechnology sectors, which drives the growth of the global cell therapy market.
Report Characteristics |
Market Size (2023) |
USD 5.9 Bn |
Forecast Value (2032) |
USD 26.2 Bn |
CAGR (2023-2032) |
17.9% |
Historical Data |
2017 - 2022 |
Forecast Data |
2023 - 2032 |
Base Year |
2022 |
Estimate Year |
2023 |
Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
Segments Covered |
By Therapy Type (Autologous Therapies and Allogenic
Therapies), By Therapeutic Area (Oncology,
Cardiovascular Disease (CVD), Musculoskeletal
Disorders, Dermatology and Others) |
Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
Prominent Players |
Novartis AG, Gilead Sciences Inc., Bristol-Myers
Squibb Company, Johnson & Johnson Services Inc.,
JCR Pharmaceutical Company Limited, Tego Science,
Atara Biotherapeutics, Takeda Pharmaceutical
Company Limited, Bluebird Bio Inc., Dendreon
Corporation and Other Key Players |
Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |
Frequently Asked Questions
The Global Cell Therapy Market is expected to reach a value of USD 5.9 billion in 2023.
The Global Cell Therapy Market is primarily focused on the research & development and production of
cell-based therapies that are primarily used in the treatment of cancer, cardiovascular disease,
musculoskeletal disorders and rare health conditions.
The key players in this market are Novartis AG, Gilead Sciences Inc., Bristol-Myers Squibb Company,
Johnson & Johnson Services Inc., JCR Pharmaceutical Company Limited, Bluebird Bio Inc., Dendreon
Corporation and others.
North America, asserts its dominance in the global cell therapy market, as it holds 67.1% of the market
share in 2023 and is expected to hold subsequent growth in the upcoming period of 2032.